As questions swirl around ATTR competition, Alnylam plots path to market leadership for Amvuttra
26th March 2026 Uncategorised 0Addressing pressing questions about the upcoming ATTR-CM competition and market opportunity, Alnylam management on Tuesday outlined a path for Amvuttra to become the revenue leader in an expansive ATTR-CM space of more than 75,000 U.S.-treated patients by 2030.
More: As questions swirl around ATTR competition, Alnylam plots path to market leadership for Amvuttra
Source: fierce